Pre-Conference Courses

​​

ISBD-ISAD 2016 Pre-Conference Courses are interactive sessions on the 13th July, 2016 requiring pre-registration (Half day course €135 / Full day course €180).  

In order to encourage audience participation and interactivity, ISBD-ISAD 2016​ limits the number of participants within each session. Tickets will be sold on a first-come first-served basis.​
Please note that space is limited, so advanced registration is strongly encouraged​.​

Full Course Information can be found below:

AGORA 1: 9:30 -12:30

BIPOLAR DISORDER IN WOMEN THROUGHOUT THE REPRODUCTIVE

LIFE CYCLE: A CASE-BASED APPROACH AND EVIDENCE-BASED GUIDELINES

Chair: Natalie Rasgon, USA

9:30-10:15 ASSESSING FEMALE-REPRODUCTIVE LIFE EVENTS IN WOMEN WITH BIPOLAR DISORDER IN THE CLINICAL PRACTICE: THE ROLE OF SCREENING, RETROSPECTIVE AND PROSPECTIVE TOOLS Benicio N.Frey, USA

10:15-11:00 SELF MANAGEMENT DURING PREGNANCY AND POSTPARTUM Anja Stevens / Bart Geerling, The Netherlands

11:00-11:45 WHAT DO THE GUIDELINES TELL US ABOUT THE MANAGEMENT OF BIPOLAR POSTPARTUM DEPRESSION? Verinder Sharma, Canada

11:45-12:30 DEPRESSION AND THE PERIMENOPAUSAL TRANSITION: A REVIEW OF THEIR ASSOCIATION, AND EVIDENCE FOR DIAGNOSIS AND MANAGEMENT William V. Bobo, USA

COURSE DESCRIPTION:

BACKGROUND: The management of bipolar disorders in women across the reproductive life cycle represents a major therapeutic challenge. Female-reproductive life events (e.g.,premenstrual and postpartum periods, transition to menopause) are associated with intense hormonal fluctuation that form a major challenge for a significant proportion of women with bipolar disorder (BD). Availability of the current clinical tools to be used in detection and diagnosis of female-related life events in women with BD is limited, leading to underdiagnosis and undertreatment of women with BD.

Treatment of women with bipolar disorder during pregnancy poses certain difficulties. Decision making on whether or not to take psychotropic medications during pregnancy requires weighing the risks for the mother and the (unborn) child.

Detection, diagnosis and treatment of bipolar depression can be particularly challenging in the postpartum period. The lack of normative data makes it difficult to distinguish symptoms of bipolar postpartum depression from the normal mood, sleep, or appetite changes women experience after childbirth. Dr. Sharma will discuss recommendations of latest treatment guidelines for the management of bipolar postpartum depression.

AIMS: We aim to provide an up-to-date, evidence-driven, case-based course, led by experts in the field of reproductive and perinatal psychiatry, on the management of bipolar disorders and depression in women across the reproductive life cycle. Specifically, the most updated literature on screening, retrospective and prospective tools tested in females with BD will be reviewed and discussed; preliminary results of a new DSM-5-based tool developed to prospectively monitor concurrent mood and premenstrual symptoms in women with and without co-morbid BD and PMDD will be presented. Planning for pregnancy and postpartum will be discussed. For treatment purposes an updated overview of recommendations from published guidelines for treating and managing bipolar disorders during pregnancy and the post-partum will be provided; also, practical approaches for both evaluation and management of perimenopausal depressive disorders and symptoms will be presented. The emphasis will be on application to clinical practice. All presentations will be formatted around actual clinical cases, and will employ electronic interactive technologies to optimize audience participation.

INTENDED AUDIENCE: The intended audience for this half-day course will be clinicians

who provide mental health care to women with severe mood disorders during their reproductive years and during the perimenopausal transition; and researchers and policymakers who are interested in the clinical complexities of managing these disorders.

FORMAT: The format will include presentations, each anchored on one or more clinical cases. Customization of course content for audience member needs will occur via interactive question and answer sessions following the first two presentation, and again after the last presentation. Acquisition of key knowledge items will be assessed and audience participation maximized via the use of electronic audience response system technology.

AURORA: 9:30 -12:30

ESSENTIAL GUIDE TO LITHIUM TREATMENT IN MOOD DISORDERS: A PRACTICAL COURSE

9:30 -10:30 LITHIUM: HISTORY, PHARMACODYNAMICS AND INDICATIONS FOR DEPRESSION AND MANIA Michael Bauer, Germany

10:30 – 11:15 MAINTENANCE TREATMENT WITH LITHIUM: PREDICTORS OF RESPONSE, PATIENT SELECTION AND SPECIAL PATIENT POPULATIONS Emanuel Severus, Germany

11:15 – 11:45 BREAK

11:45​ -12:30 PRACTICAL GUIDE OF LITHIUM THERAPY AND MANAGEMENT OF SIDE EFFECTS Michael Gitlin, USA

COURSE DESCRIPTION:

Pharmacological treatment with mood stabilizers is essential for the long-term (relapse-preventive) treatment of bipolar disorder. More  than 60  years from  the  breakthrough of identifying lithium salts to have antimanic  and  prophylactic  activity, modem  research  serves  to   further  substantiate lithium's position at the  front-line in  the  treatment of bipolar disorder. Undoubtedly, lithium is an essential medication for patients with mood disorders and represents the most valuable treatment option in the long-term treatment of bipolar disorders. When used correctly, lithium unquestionably produces the most dramatic benefits of any medication in psychopharmacology. Two recent meta­ analyses confirmed its efficacy regarding the prevention of overall mood episodes, manic episodes, depressive episodes (dependent on the type of analyses performed) and acceptability (completion of study). Despite of this and the  fact  that lithium is  consistently ranked as first choice for  the  long­ term treatment of  bipolar disorders in  international  treatment  guidelines lithium is  dramatically underutilized in  clinical practice in  many countries. Since its introduction in  modern psychiatry in 1949,  many  new   aspects  of  its  use in   psychiatry  have   been  discovered  in   basic  and  clinical research, including anti-suicidal and  antidepressant  properties. Despite the   successes achieved through application of lithium treatment, the drug remains an ineffective option for a proportion of bipolar patients. Not all patients are so-called 'lithium responders' and it has become a task of great importance to be able to establish whether or not a given patient will benefit from its treatment. It is also  important to establish whether even  non-responders to  mood  stabilizing effects of lithium may still  benefit from  some of the  other actions of this element (e.g.,  from  its anti-suicidal effects). The major questions are who is getting lithium, at which point, and what algorithm can be offered in case a patients fails   to first/ second and further options, monotherapy vs. combination therapy. These questions  will  be  addressed in  this course which is  a  practical guide for  all  health care professionals, patients and their caregivers with  up-to-date information about the correct use of lithium in various indications  (maintenance, depression, mania,  suicide  prevention). This course will be organized by 3 international experts in the treatment of mood disorders who have more than 25 years of experience in the administration of lithium, have authored numerous scientific articles on lithium, and are also heading the ongoing ISBD Task Force "Lithium" (M.B and E.S) knowledge they will require in short and long-term treatment.

This course will:

1) Give an evidence-based overview on the various indications of lithium including efficacy, strength and weaknesses, adverse events and its management

2) Present "good clinical practice" how to use lithium medication (and how to avoid intoxications) properly

3)  Give an overview of lithium's position in currently available evidence-based treatment guidelines.

4) Discuss how to effectively select the right patient for the individual indication (attempts to personalize treatment).

5) Discuss the most important clinical issues with case vignettes.

6) Encourage participants beforehand to bring their own case vignettes of difficult-to-treat patients.

Supporting materials (pre-read):

Bauer M, Gitlin  M. The essential guide to lithium treatment: a practical manual. Springer

Heidelberg New York 2016

Haussmann R, Bauer M, von Bonin S, Grof P, Lewitzka U. Treatment of lithium intoxication: facing the need for evidence. lnt J Bipolar Disord. 2015;3(1):23

Lewitzka U, Severns E, Bauer R, Ritter P, Muller-Oerlinghausen B, Bauer M. The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review.  lnt J Bipolar Disord. 2015b; 3(1):32

Miura T, Noma  H, Furukawa T, Mitsuyasu H, Tanaka S, Stockton Setal. (Eds):Comparative efficacy and  tolerability of  pharmacological treatments  in   the   maintenance  treatment  of  bipolar disorder: a systematic review  and  network meta-analysis.  Lancet Psychiatry 2015, 1:  351-359.

Severns E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR.  Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int  J Bipolar Disord. 2014;20(2):15

Yatham LN, Kennedy SH,  Parikh SV,  Schaffer A, Beaulieu S,  Aida  M et al.:  Canadian Network  for Mood  and  Anxiety Treatments  (CANMAT) and  International  Society for  Bipolar Disorders (ISBD)  collaborative update  of  CANMAT guidelines for   the   management of  patients  with bipolar disorder: update 2013. Bipolar Disord 2013.

AGORA 2: 9:30 -12:30

CLINICAL TRANSLATION OF EVIDENCE-BASED MEDICINE IN BIPOLAR DISORDER

9:30 -9:45 WELCOME & OVERVIEW OF AUDIENCE RESPONSE SYSTEM (ARS) TECHNOLOGY Mark A. Frye, USA

9:45 - 10:15 MANIA MATTERS: CASE-BASED REVIEW Gin Malhi, Australia

10:15 - 10:45 MISMATCH BETWEEN PREVALENCE & EVIDENCE: CASE-BASED BIPOLAR DEPRESSION  William V. Bobo, USA

10:45 - 11:15 ROAD TO RECOVERY: CASE-BASED MAINTENANCE PHASE OF BIPOLAR DISORDER Aysegul Ozerdem, Turkey

11:15 - 11:45 MULTIFACETED BIPOLAR DISORDER: CASE-BASED COMORBIDITIES & DUAL DIAGNOSIS Mark A.Frye, USA

11:45 – 12:30 Q and A

COURSE DESCRIPTION

Evidence-based medicine (EBM) is individualizing treatment recommendations in clinical practice based on well designed, controlled research. The translation of EBM to everyday, community based psychiatric care, however continues to be a challenge.  This is, in part, related to the rigor of regulatory trial design and translational difficulties in dissemination to community based practitioners.  Focused continuing medical education that is case-based, resembling practice, will enhance EBM guiding optimal psychiatric care.

This course, designed for the clinical practicing psychiatrist and mental health professional, will review bipolar clinical cases from the Mayo Clinic Depression Center,the Cade Clinic of the Royal North Shore Hospital, and the Dokuz Eylul University Health Science Institute. Case-based presentations will review the evidence base for mania,bipolar depression,maintenance phase bipolar  disorder,and bipolar  disorder with various comorbidities with a focus on how best to individualize treatments for patients. Utilizing audience response system (ARS) technology, participants will provide an initial treatment recommendation based on clinical experience, and as each case unfolds with a review of the evidence base, a final recommendation. This exercise will provide active learning during the course to enhance the clinician's ability to critically review evidence-based medicine with a translation into their clinical practice.

AGORA 3: 9:30 -16:00

LONGITUDINAL HIGH-RISK STUDIES OF THE OFFSPRING OF BIPOLAR PARENTS:  TWO DECADES OF RESEARCH AND CLINICAL EXPERIENCE

9:30 WELCOME REMARKS AND TIME TO DESIGN YOUR OWN HIGH-RISK STUDY​Manon Hillegers, The Netherlands

10:00  AN INTRODUCTION TO HIGH RISK STUDY DESIGN, COMPARISON GROUP SELECTION, AND STATISTICAL APPROACHES TO LONGITUDINAL DATA.Martin Preisig, Switzerland

10:30 IMPORTANT PARENTAL FACTORS THAT INFLUENCE OUTCOMES IN HIGH-RISK OFFSPRING STUDIES​ Anne Duffy, Canada

11.00 DEVELOPMENTAL, CLINICAL AND COGNITIVE HETEROGENEITY AMONG OFFSPRING AND PARENTS​ Melissa Green and Philip Mitchell, Australia

11:45 THE IMPACT OF CROSS-NATIONAL DIFFERENCES ON PSYCHOPATHOLOGY OUTCOMES IN HIGH-RISK OFFSPRING Manon Hillegers, The Netherlands

12:15 TIME TO REVISE HIGH-RISK STUDY DESIGNS IN CONSULT WITH PRESENTERS​

13:00 LUNCH BREAK

14:00 PSYCHOSOCIAL INTERVENTIONS IN THE EARLY STAGES OF BIPOLAR DISORDER: CONSIDERING THE FAMILIAL CONTEXT , David Miklowitz, USA 

14:30 CLINICAL APPROACHES TO HIGH-RISK YOUTH: TREATMENT DILEMMAS David Miklowitz, USAManon Hillegers,The Netherlands and Anne Duffy, Canada

15:30 ​INTEGRATION AND GENERAL DISCUSSION Manon Hillegers,The Netherlands and Anne Duffy, Canada

COURSE DESCRIPTION:

There are recognizable clinical indicators of developing bipolar disorder (BD) long before diagnosable hypomanic/manic episodes manifest. Given the high heritability and complexity of BD, it makes sense to study the offspring of affected parents in order to map changes related to illness development at multiple levels (i.e. clinical, psychological, neural, biological). This course will include short lectures and interactive sessions to help you design your own high-risk study.  Specifically, participants will be asked at the outset to develop a basic high-risk study given their particular circumstances and interests. Then a general introduction to high-risk study designs and implications for analyses will be presented, including selection of appropriate comparison groups, consideration of approaches to longitudinal repeated measures and managing confounds. In addition, methodological aspects of high-risk studies that affect outcomes will be discussed, focusing on the approach to recruitment and confirmation of the diagnosis in the bipolar parent, heterogeneity, and inclusion of comorbidity and cross-disorder effects in the co-parent. With regard to the offspring, considerations regarding age range, comorbidity, and cross-national differences in reported psychopathology will be discussed in light of methodological and diagnos​tic conceptual differences. Following these presentations, participants will be su​pported to revise their study designs with presenters available for consultation. The afternoon sessions will focus on clinical issues that arise with presentations relating to the families, the psychosocial context of high-risk offspring of a BD parent and the elements of developing a family psycho-educational intervention will be presented. Finally, the clinical applicability of the high-risk research outcomes will be discussed and interactively illustrated with clinical examples. Participants are encouraged to present questions from their own clinical experience. ​

INTENDED AUDIENCE:

Clinicians, investigators, research trainees interested in designing and conducting high-risk studies.

AGORA 2: 13:00 – 16:00

STATE OF THE ART IN DIAGNOSING, ASSESSING AND TREATING BIPOLAR DISORDER: A TRAINING COURSE TO IMPROVE YOUR SKILLS AS A BIPOLAR EXPERT

13:00 - 13:45  INTRODUCTION: CONCEPTS AND DIAGNOSIS OF BIPOLAR DISORDER IN ADULTS Ralph Kupka, The Netherlands

Introduction to the course program and the concept(s) of bipolar disorder. How to recognize and diagnose patients with bipolar disorder; pitfalls and blind spots; differential diagnostic issues (unipolar depression and borderline personality disorder); using diagnostic tools and rating scales.

13:45 - 14:15  PSYCHOTHERAPY AND PSYCHOEDUCATION Francesc Colom , Spain​

Evidence based psychotherapies: which, when, and for whom? Psychoeducation in individual and group formats.

14:15 - 14:30 BREAK

14:30 - 15:15  ACUTE PHARMACOTHERAPY FOR MANIA AND DEPRESSION Willem Nolen The Netherlands & Joseph Calabrese USA

15:15 - 16:00 MAINTENANCE PHARMACOTHERAPY Willem Nolen The Netherlands & Joseph Calabrese USA

INTRODUCTION: Bipolar disorder is a heterogeneous clinical condition, confronting clinicians with diagnostic dilemma's and complex treatment decisions. This course provides an overview for clinicians who are relatively new in the field of bipolar disorder, addressing the diagnostic process using the new DSM-5 classification and going beyond classification in real world clinical practice, and how to treat (psychologically and pharmacologically) patients with bipolar disorder. The course will include 4 sessions of 45 minutes each, consisting of presentations by experts on the topics, alternated with extensive discussions and including exercises using clinical case vignettes, to ensure much interaction with the course participants. Basic elements as well as some controversial issues and common pitfalls are presented and interactively illustrated with clinical examples. Participants are encouraged to presen​t questions and dilemmas from their own experience.

PARTICIPANTS: Up to 30 psychiatrists and psychologists (including residents and trainees) who want to increase or update their skills to become an expert clinician in bipolar disorder.​


14th July, 2016 - AGORA 2 : 9:00 -12:00

​HOW TO ACHIEVE PUBLISHING SUCCESS

9:00 -9:10 HOW HAS PUBLISHING CHANGED AND HOW IS LIKELY TO CHANGE IN THE NEAR FUTURE? AND WHO PUBLISHES AND WHY?Allan H Young, UK   

9:10 -9:20 WHAT JOURNAL SHOULD I PUBLISH IN? AND WHAT DOES AN IDEAL PAPER LOOK LIKE? ​Gin Malhi, Australia

9:20 -9:40 DISCUSSION OF ABOVE TWO PRESENTATIONS 1 & 2.                           

9:40 -9:50 WHAT ARE THE COMMON PROBLEMS THAT EDITORS IDENTIFY EARLY THAT LEAD TO REJECTION OF A PAPER? Jair Soares, USA

9:50 -10:00 WHAT ARE THE PROBLEMS THAT REVIEWERS IDENTIFY THAT LEAD TO REJECTION OF A PAPER? Paolo Brambilla, USA

10:00 -10:20  DISCUSSION OF ABOVE TWO PRESENTATIONS 3 & 4. 

10:20 -10:35   BREAK                                                                                              

10:35 – 10:50 HOW TO RESPOND TO REVIEWERS' COMMENTS, AND CREATE A REVISION THAT WILL ENSURE SUCCESS? Gin Malhi, Australia

10:50 -11:00 WHAT TO DO IF A PAPER IS ULTIMATELY REJECTED?                       Jair Soares, USA

11:00 -11:20 DISCUSSION OF ABOVE TWO PRESENTATIONS 5 & 6.                         

11:20 -12:00  PANEL DISCUSSION                                                                                  ​

​ 


Keep Me Updated